TY - JOUR
T1 - The second nationwide surveillance of the antimicrobial susceptibility of Neisseria gonorrhoeae from male urethritis in Japan, 2012-2013
AU - Hamasuna, Ryoichi
AU - Yasuda, Mitsuru
AU - Ishikawa, Kiyohito
AU - Uehara, Shinya
AU - Hayami, Hiroshi
AU - Takahashi, Satoshi
AU - Matsumoto, Tetsuro
AU - Yamamoto, Shingo
AU - Minamitani, Shinichi
AU - Watanabe, Akira
AU - Iwata, Satoshi
AU - Kaku, Mitsuo
AU - Kadota, Junichi
AU - Sunakawa, Keisuke
AU - Sato, Junko
AU - Hanaki, Hideaki
AU - Tsukamoto, Taiji
AU - Kiyota, Hiroshi
AU - Egawa, Shin
AU - Tanaka, Kazushi
AU - Arakawa, Soichi
AU - Fujisawa, Masato
AU - Kumon, Hiromi
AU - Kobayashi, Kanao
AU - Matsubara, Akio
AU - Naito, Seiji
AU - Kuroiwa, Kentaro
AU - Hirayama, Hideo
AU - Narita, Harunori
AU - Hosobe, Takahide
AU - Ito, Shin
AU - Ito, Kenji
AU - Kawai, Shuichi
AU - Ito, Masayasu
AU - Chokyu, Hirofumi
AU - Matsumura, Masaru
AU - Yoshioka, Masaru
AU - Uno, Satoshi
AU - Monden, Koichi
AU - Takayama, Kazuo
AU - Kaji, Shinichi
AU - Kawahara, Motoshi
AU - Sumii, Toru
AU - Kadena, Hitoshi
AU - Yamaguchi, Takamasa
AU - Maeda, Shinichi
AU - Nishi, Shohei
AU - Nishimura, Hirofumi
AU - Shirane, Takeshi
AU - Yoh, Mutsumasa
AU - Akiyama, Kikuo
AU - Imai, Toshio
AU - Kano, Motonori
N1 - Funding Information:
Mitsuru Yasuda has received donation from Astellas Pharma Inc. Akira Watanabe has received speaker's honorarium from MSD K.K., Glaxo SmithKline K.K., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd. and Pfizer Japan Inc.; grant support from Kyorin Pharmaceutical Co., Ltd. , Shionogi & Co., Ltd .
Funding Information:
Taisho Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd., Daiichi Sankyo Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Taiho Pharmaceutical Co., Ltd. and Meiji Seika Pharma Co., Ltd. Satoshi Iwata has received speaker's honorarium from Astellas Pharma Inc., Pfizer Japan Inc., Taisho Toyama Pharmaceutical Co., Ltd., MSD K.K., Meiji Seika Pharma Co., Ltd., Daiichi Sankyo Co., Ltd. and Japan Vaccine Co., Ltd., donation from Taisho Toyama Pharmaceutical Co., Ltd. and supported, in part, by a fund from Nikon Corporation . Mitsuo Kaku has received speaker's honorarium from Taisho Toyama Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Pfizer Japan Inc. and Sumitomo Dainippon Pharma Co., Ltd. and donation from Astellas Pharma Inc. Junichi Kadota has received speaker's honorarium from Taisho Toyama Pharmaceutical Co., Ltd., Pfizer Japan Inc., MSD K.K., Kyorin Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Glaxo SmithKline K.K., payments for a manuscript drafting and editing from Nankodo Co., Ltd. and donation from Astellas Pharma Inc. Keisuke Sunakawa has received speaker's honorarium from Taisho Toyama Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd. and Meiji Seika Pharma Co., Ltd. Hideaki Hanaki is a member of a laboratory endowed chair from Kohjin Bio Co., Ltd. Taiji Tsukamoto has received speaker's honorarium from Astellas Pharma Inc., and payments for a manuscript drafting and editing from RichHill Medical Inc. Shin Egawa has received donation from Takeda Pharmaceutical Co., Ltd., Astellas Pharma Inc., Asahi Kasei Corp. and Euro Meditech Co., Ltd. Soichi Arakawa has received speaker's honorarium from Taisho Toyama Pharmaceutical Co., Ltd.
Publisher Copyright:
© 2015 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases.
PY - 2015
Y1 - 2015
N2 - Worldwide, the most important concern in the treatment of sexually transmitted infections is the increase in antimicrobial resistant Neisseria gonorrhoeae strains including resistance to cephalosporins, penicillins, fluoroquinolones or macrolides. To investigate the trends of antimicrobial susceptibility among N.gonorrhoeae strains isolated from male patients with urethritis, a Japanese surveillance committee conducted the second nationwide surveillance study. Urethral discharge was collected from male patients with urethritis at 26 medical facilities from March 2012 to January 2013. Of the 151 specimens, 103 N.gonorrhoeae strains were tested for susceptibility to 20 antimicrobial agents. None of the strains was resistant to ceftriaxone, but the minimum inhibitory concentration (MIC) 90% of ceftriaxone increased to 0.125 μg/ml, and 11 (10.7%) strains were considered less susceptible with an MIC of 0.125 μg/ml. There were 11 strains resistant to cefixime, and the MICs of these strains were 0.5μg/ml. The distributions of the MICs of fluoroquinolones, such as ciprofloxacin, levofloxacin and tosufloxacin, were bimodal. Sitafloxacin, a fluoroquinolone, showed strong activity against all strains, including strains resistant to other three fluoroquinolones, such as ciprofloxacin, levofloxacin and tosufloxacin. The azithromycin MICs in 2 strains were 1μg/ml.
AB - Worldwide, the most important concern in the treatment of sexually transmitted infections is the increase in antimicrobial resistant Neisseria gonorrhoeae strains including resistance to cephalosporins, penicillins, fluoroquinolones or macrolides. To investigate the trends of antimicrobial susceptibility among N.gonorrhoeae strains isolated from male patients with urethritis, a Japanese surveillance committee conducted the second nationwide surveillance study. Urethral discharge was collected from male patients with urethritis at 26 medical facilities from March 2012 to January 2013. Of the 151 specimens, 103 N.gonorrhoeae strains were tested for susceptibility to 20 antimicrobial agents. None of the strains was resistant to ceftriaxone, but the minimum inhibitory concentration (MIC) 90% of ceftriaxone increased to 0.125 μg/ml, and 11 (10.7%) strains were considered less susceptible with an MIC of 0.125 μg/ml. There were 11 strains resistant to cefixime, and the MICs of these strains were 0.5μg/ml. The distributions of the MICs of fluoroquinolones, such as ciprofloxacin, levofloxacin and tosufloxacin, were bimodal. Sitafloxacin, a fluoroquinolone, showed strong activity against all strains, including strains resistant to other three fluoroquinolones, such as ciprofloxacin, levofloxacin and tosufloxacin. The azithromycin MICs in 2 strains were 1μg/ml.
UR - http://www.scopus.com/inward/record.url?scp=84933049453&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84933049453&partnerID=8YFLogxK
U2 - 10.1016/j.jiac.2015.01.010
DO - 10.1016/j.jiac.2015.01.010
M3 - Article
C2 - 25727286
AN - SCOPUS:84933049453
SN - 1341-321X
VL - 21
SP - 340
EP - 345
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
IS - 5
ER -